Cargando…

Biological factors that place women at risk for HIV: evidence from a large-scale clinical trial in Durban

BACKGROUND: It is well documented that the mucosal linings of the female genital tract (FGT) usually provides a robust barrier that protects against sexually acquired infections. However, to the best of our knowledge there are limited South African studies that have investigated the association betw...

Descripción completa

Detalles Bibliográficos
Autores principales: Abbai, Nathlee Samantha, Wand, Handan, Ramjee, Gita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799526/
https://www.ncbi.nlm.nih.gov/pubmed/26992693
http://dx.doi.org/10.1186/s12905-016-0295-5
_version_ 1782422364112289792
author Abbai, Nathlee Samantha
Wand, Handan
Ramjee, Gita
author_facet Abbai, Nathlee Samantha
Wand, Handan
Ramjee, Gita
author_sort Abbai, Nathlee Samantha
collection PubMed
description BACKGROUND: It is well documented that the mucosal linings of the female genital tract (FGT) usually provides a robust barrier that protects against sexually acquired infections. However, to the best of our knowledge there are limited South African studies that have investigated the association between damage to the mucosal linings and the acquisition of HIV infections. We hypothesize that in this cohort of women, a higher rate of HIV seroconversions will be observed for women who present with evidence of mucosal damage. METHODS: We undertook a secondary analysis of the Methods for Improving Reproductive Health in Africa (MIRA) trial that assessed the effectiveness of the latex diaphragm and lubricant gel on HIV prevention among women. Participants underwent a physical examination which included a pelvic examination to detect the presence of mucosal abnormalities. During the physical examinations, the study clinicians examined the genitalia, cervix and vagina for signs of epithelial disruptions and abnormal vaginal discharge. The association between the various genital factors and HIV seroconversion was modeled using Cox proportional hazards regression analysis. RESULTS: In this cohort of 1485 women that had enrolled to participate in the study, women that had presented with genital epithelial disruptions and abnormal vaginal discharge were shown to be at highest risk for HIV acquisition (Hazard Ratio (HR): 4.30, 95 % CI: 2.25, 8.22, p <0001, HR: 2.37, 95 % CI: 1.69, 3.33, p <0.001) respectively. In addition, the Kaplan Meier analysis showed that the highest number of seroconversions was observed in women that had disrupted genital epithelia (27 per 100/py, 95 % CI: 15.0, 50.7) and abnormal vaginal discharge (12 per 100/py, 95 % CI: 9.70, 16.7). Other significant factors included: genital signs and symptoms (HR: 1.67, 95 % CI: 1.07, 2.61, p = 0.02) and genital ulcers/sores (HR: 1.79, 95 % CI: 1.05, 3.06, p = 0.03). CONCLUSION: We have shown that damage to the mucosal epithelial lining increases a women’s risk of HIV seroconversion. Future studies that provide an in depth understanding of the mechanisms associated with the FGT and mucosal immunity will be most valuable. An understanding of all of these mechanisms will be key in directing the advancement of products most suitable for combating HIV infection in women. TRIAL REGISTRATION: This study was registered with ClinicalTrials.gov,number NCT00121459 on the 28(th) February 2007.
format Online
Article
Text
id pubmed-4799526
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47995262016-03-20 Biological factors that place women at risk for HIV: evidence from a large-scale clinical trial in Durban Abbai, Nathlee Samantha Wand, Handan Ramjee, Gita BMC Womens Health Research Article BACKGROUND: It is well documented that the mucosal linings of the female genital tract (FGT) usually provides a robust barrier that protects against sexually acquired infections. However, to the best of our knowledge there are limited South African studies that have investigated the association between damage to the mucosal linings and the acquisition of HIV infections. We hypothesize that in this cohort of women, a higher rate of HIV seroconversions will be observed for women who present with evidence of mucosal damage. METHODS: We undertook a secondary analysis of the Methods for Improving Reproductive Health in Africa (MIRA) trial that assessed the effectiveness of the latex diaphragm and lubricant gel on HIV prevention among women. Participants underwent a physical examination which included a pelvic examination to detect the presence of mucosal abnormalities. During the physical examinations, the study clinicians examined the genitalia, cervix and vagina for signs of epithelial disruptions and abnormal vaginal discharge. The association between the various genital factors and HIV seroconversion was modeled using Cox proportional hazards regression analysis. RESULTS: In this cohort of 1485 women that had enrolled to participate in the study, women that had presented with genital epithelial disruptions and abnormal vaginal discharge were shown to be at highest risk for HIV acquisition (Hazard Ratio (HR): 4.30, 95 % CI: 2.25, 8.22, p <0001, HR: 2.37, 95 % CI: 1.69, 3.33, p <0.001) respectively. In addition, the Kaplan Meier analysis showed that the highest number of seroconversions was observed in women that had disrupted genital epithelia (27 per 100/py, 95 % CI: 15.0, 50.7) and abnormal vaginal discharge (12 per 100/py, 95 % CI: 9.70, 16.7). Other significant factors included: genital signs and symptoms (HR: 1.67, 95 % CI: 1.07, 2.61, p = 0.02) and genital ulcers/sores (HR: 1.79, 95 % CI: 1.05, 3.06, p = 0.03). CONCLUSION: We have shown that damage to the mucosal epithelial lining increases a women’s risk of HIV seroconversion. Future studies that provide an in depth understanding of the mechanisms associated with the FGT and mucosal immunity will be most valuable. An understanding of all of these mechanisms will be key in directing the advancement of products most suitable for combating HIV infection in women. TRIAL REGISTRATION: This study was registered with ClinicalTrials.gov,number NCT00121459 on the 28(th) February 2007. BioMed Central 2016-03-19 /pmc/articles/PMC4799526/ /pubmed/26992693 http://dx.doi.org/10.1186/s12905-016-0295-5 Text en © Abbai et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Abbai, Nathlee Samantha
Wand, Handan
Ramjee, Gita
Biological factors that place women at risk for HIV: evidence from a large-scale clinical trial in Durban
title Biological factors that place women at risk for HIV: evidence from a large-scale clinical trial in Durban
title_full Biological factors that place women at risk for HIV: evidence from a large-scale clinical trial in Durban
title_fullStr Biological factors that place women at risk for HIV: evidence from a large-scale clinical trial in Durban
title_full_unstemmed Biological factors that place women at risk for HIV: evidence from a large-scale clinical trial in Durban
title_short Biological factors that place women at risk for HIV: evidence from a large-scale clinical trial in Durban
title_sort biological factors that place women at risk for hiv: evidence from a large-scale clinical trial in durban
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799526/
https://www.ncbi.nlm.nih.gov/pubmed/26992693
http://dx.doi.org/10.1186/s12905-016-0295-5
work_keys_str_mv AT abbainathleesamantha biologicalfactorsthatplacewomenatriskforhivevidencefromalargescaleclinicaltrialindurban
AT wandhandan biologicalfactorsthatplacewomenatriskforhivevidencefromalargescaleclinicaltrialindurban
AT ramjeegita biologicalfactorsthatplacewomenatriskforhivevidencefromalargescaleclinicaltrialindurban